iNtRON Biotechnology, Inc. (048530.KQ)

KRW 5500.0

(-4.35%)

Total Assets Summary of iNtRON Biotechnology, Inc.

iNtRON Biotechnology, Inc.'s latest annual total assets in 2023 was 98.61 Billion KRW , down -30.04% from previous year.
iNtRON Biotechnology, Inc.'s latest quarterly total assets in 2024 Q2 was 94.84 Billion KRW , down -3.48% from previous quarter.
iNtRON Biotechnology, Inc. reported annual total assets of 140.95 Billion KRW in 2022, down -8.09% from previous year.
iNtRON Biotechnology, Inc. reported annual total assets of 153.36 Billion KRW in 2021, up 52.55% from previous year.
iNtRON Biotechnology, Inc. reported quarterly total assets of 98.26 Billion KRW for 2024 Q1, down -0.35% from previous quarter.
iNtRON Biotechnology, Inc. reported quarterly total assets of 99.31 Billion KRW for 2023 Q3, down -28.41% from previous quarter.

Annual Total Assets Chart of iNtRON Biotechnology, Inc. (2023 - 2012)

Historical Annual Total Assets of iNtRON Biotechnology, Inc. (2023 - 2012)

Year	Total Assets	Total Assets Growth
2023	98.61 Billion KRW	-30.04%
2022	140.95 Billion KRW	-8.09%
2021	153.36 Billion KRW	52.55%
2020	100.53 Billion KRW	12.92%
2019	89.03 Billion KRW	62.48%
2018	54.79 Billion KRW	20.09%
2017	45.62 Billion KRW	-23.45%
2016	59.6 Billion KRW	47.65%
2015	40.36 Billion KRW	0.0%
2012	19.64 Billion KRW	0.0%

Year	Total Assets	Total Assets Growth
2024 Q2	94.84 Billion KRW	-3.48%
2024 Q1	98.26 Billion KRW	-0.35%
2023 Q3	99.31 Billion KRW	-28.41%
2023 Q1	139.41 Billion KRW	-1.09%
2023 FY	98.61 Billion KRW	-30.04%
2023 Q2	138.72 Billion KRW	-0.5%
2023 Q4	98.61 Billion KRW	-0.71%
2022 FY	140.95 Billion KRW	-8.09%
2022 Q4	140.95 Billion KRW	-4.51%
2022 Q3	147.61 Billion KRW	-2.83%
2022 Q2	151.92 Billion KRW	-2.52%
2022 Q1	155.85 Billion KRW	1.62%
2021 Q3	149.48 Billion KRW	40.29%
2021 Q4	153.36 Billion KRW	2.6%
2021 FY	153.36 Billion KRW	52.55%
2021 Q1	102.56 Billion KRW	2.02%
2021 Q2	106.55 Billion KRW	3.88%
2020 FY	100.53 Billion KRW	12.92%
2020 Q1	88.84 Billion KRW	-0.21%
2020 Q4	100.53 Billion KRW	1.38%
2020 Q3	99.16 Billion KRW	-3.92%
2020 Q2	103.21 Billion KRW	16.17%
2019 Q3	91.91 Billion KRW	0.46%
2019 FY	89.03 Billion KRW	62.48%
2019 Q1	54.5 Billion KRW	-0.53%
2019 Q4	89.03 Billion KRW	-3.14%
2019 Q2	91.49 Billion KRW	67.87%
2018 Q4	54.79 Billion KRW	22.81%
2018 FY	54.79 Billion KRW	20.09%
2018 Q3	44.61 Billion KRW	-2.6%
2018 Q2	45.8 Billion KRW	3.82%
2018 Q1	44.12 Billion KRW	-3.3%
2017 Q1	58.92 Billion KRW	20.05%
2017 FY	45.62 Billion KRW	-23.45%
2017 Q4	45.62 Billion KRW	-24.86%
2017 Q3	60.72 Billion KRW	-2.3%
2017 Q2	62.15 Billion KRW	5.47%
2016 Q4	49.08 Billion KRW	0.0%
2016 Q1	- KRW	0.0%
2016 FY	59.6 Billion KRW	47.65%
2015 FY	40.36 Billion KRW	0.0%
2013 Q3	23.04 Billion KRW	11.78%
2013 Q2	20.61 Billion KRW	-0.95%
2013 Q1	20.81 Billion KRW	5.93%
2012 FY	19.64 Billion KRW	0.0%
2012 Q4	19.64 Billion KRW	4.4%
2012 Q3	18.81 Billion KRW	0.0%

Peer Total Assets Comparison of iNtRON Biotechnology, Inc.

Name	Total Assets	Total Assets Difference
HLB Co., Ltd.	751.72 Billion KRW	86.882%
BINEX Co., Ltd.	257.01 Billion KRW	61.63%
Bioneer Corporation	315.48 Billion KRW	68.742%
Anterogen.Co.,Ltd.	149.43 Billion KRW	34.007%
MEDIPOST Co., Ltd.	449.39 Billion KRW	78.056%
CrystalGenomics, Inc.	243.11 Billion USD	59.437%
Helixmith Co., Ltd	227.27 Billion KRW	56.611%
Chabiotech Co.,Ltd.	1725.57 Billion KRW	94.285%
Medy-Tox Inc.	611.62 Billion KRW	83.877%
Peptron, Inc.	52.49 Billion KRW	-87.852%
Amicogen, Inc.	467.09 Billion KRW	78.888%
Genexine, Inc.	376.58 Billion KRW	73.814%
HLB Therapeutics Co.,Ltd.	200.79 Billion KRW	50.888%
LegoChem Biosciences, Inc.	189.5 Billion KRW	47.961%
ALTEOGEN Inc.	256.09 Billion KRW	61.494%
PharmaResearch Co., Ltd.	535.28 Billion KRW	81.577%
SillaJen, Inc.	76.71 Billion KRW	-28.547%
JETEMA, Co., Ltd.	252.14 Billion KRW	60.89%
OliX Pharmaceuticals,Inc	102.82 Billion KRW	4.095%
Genomictree Inc.	132.84 Billion KRW	25.767%
MedPacto, Inc.	80.47 Billion KRW	-22.542%
D&D Pharmatech	79.2 Billion KRW	-24.508%
EASY BIO,Inc.	172.04 Billion KRW	42.68%
GI Innovation, Inc.	81.34 Billion KRW	-21.237%